Bone targeted therapy in breast cancer: Present and future

Critical Reviews in Oncology/Hematology

Volumn 74, Issue SUPPL. 1, 2010, Pages S7-

  Huober, Jens ^a   Thürlimann, Beat ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; LETROZOLE; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 77952302459     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(10)70004-4     Document Type: Review

References (23)

1. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
2. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999, 17:846-854.
3. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001, 91:1191-1200.
4. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
5. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
6. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008, 112:1001-1010.
7. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
8. Braun S, Vogel F, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802.
9. Powles T, Paterson S, Kanis JA, et al. Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224.
10. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006, 8:1-7.
11. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
12. Saarto T, Vehmanen L, Virkkunen P, et al. Ten-year follow up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2003, 43:650-656.
13. Diel IJ, Solomayer E, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
14. Diel IJ, Jaschke A, Solomayer E, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long term follow up. Ann Oncol 2008, 19:2007-2011.
15. Kristensen B, Ejlertsen B, Mouridsen H, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008, 47:740-746.
16. Gnant M, Eidtmann H The anti-tumor effect of bisphosphonates -ABCSG-12, ZO-FAST and more .... Crit Rev Oncol Hematol 2010, 74(1):S2-S6.
17. Diel I, Aebi S Routine adjuvant use of bisphosphonates in breast cancer - Arguments in favour and against. Crit Rev Oncol Hematol 2010, 74(1):S11-S15.
18. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007, 25:4431-4437.
19. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1546-1571.
20. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. EJC Suppl 2009, 7(3):2. [abstract 2LBA].
21. Stopeck A, de Boer R, Fujiwara Y, et al. Comparison of denosumab versus zoledronic acid on the incidence of skeletal-related events in breast cancer patients with bone metastases. Cancer Res 2009, 69(suppl). abstract 22.
22. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882.
23. Background documentation for meeting of Advisory Committee for reproductive health drugs (August 13, 2009). Denosumab http://www.fda.gov.